These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18594798)

  • 1. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
    Varty GB; Hodgson RA; Pond AJ; Grzelak ME; Parker EM; Hunter JC
    Psychopharmacology (Berl); 2008 Oct; 200(3):393-401. PubMed ID: 18594798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
    Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
    Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration.
    Ward RP; Dorsa DM
    Neuroscience; 1999 Mar; 89(3):927-38. PubMed ID: 10199625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
    Bleickardt CJ; Kazdoba TM; Jones NT; Hunter JC; Hodgson RA
    Pharmacol Biochem Behav; 2014 Mar; 118():36-45. PubMed ID: 24211858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum.
    Wardas J; Pietraszek M; Dziedzicka-Wasylewska M
    Brain Res; 2003 Jul; 977(2):270-7. PubMed ID: 12834887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine A2A receptors and depression.
    El Yacoubi M; Costentin J; Vaugeois JM
    Neurology; 2003 Dec; 61(11 Suppl 6):S82-7. PubMed ID: 14663017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
    Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
    Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
    Hodgson RA; Bedard PJ; Varty GB; Kazdoba TM; Di Paolo T; Grzelak ME; Pond AJ; Hadjtahar A; Belanger N; Gregoire L; Dare A; Neustadt BR; Stamford AW; Hunter JC
    Exp Neurol; 2010 Oct; 225(2):384-90. PubMed ID: 20655910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
    Xue Y; Chen L
    Neurosci Bull; 2010 Oct; 26(5):345-54. PubMed ID: 20882060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors.
    Higgins GA; Grzelak ME; Pond AJ; Cohen-Williams ME; Hodgson RA; Varty GB
    Behav Brain Res; 2007 Dec; 185(1):32-42. PubMed ID: 17707919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
    Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.
    Salamone JD; Farrar AM; Font L; Patel V; Schlar DE; Nunes EJ; Collins LE; Sager TN
    Behav Brain Res; 2009 Jul; 201(1):216-22. PubMed ID: 19428636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol-induced catalepsy is influenced by adenosine receptor antagonists.
    Malec D
    Pol J Pharmacol; 1997; 49(5):323-7. PubMed ID: 9566031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.
    El Yacoubi M; Ledent C; Parmentier M; Bertorelli R; Ongini E; Costentin J; Vaugeois JM
    Br J Pharmacol; 2001 Sep; 134(1):68-77. PubMed ID: 11522598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
    Mori A; Shindou T
    Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.
    Trevitt J; Vallance C; Harris A; Goode T
    Pharmacol Biochem Behav; 2009 May; 92(3):521-7. PubMed ID: 19463269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.
    Yang M; Soohoo D; Soelaiman S; Kalla R; Zablocki J; Chu N; Leung K; Yao L; Diamond I; Belardinelli L; Shryock JC
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):133-44. PubMed ID: 17310264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on Δ9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys.
    Justinová Z; Redhi GH; Goldberg SR; Ferré S
    J Neurosci; 2014 May; 34(19):6480-4. PubMed ID: 24806674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.